Gemlapodect

Phase 2Small molecule

NNoema Pharma AG

Gemlapodect is one of 31 small molecule programs targeting Tourette syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tourette SyndromeActive, not recruiting

Tourette SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Tourette Syndrome

#DrugCompanyPhaseTrials

Marinol

Alnylam Pharmaceuticals

Epidiolex

Rilutek

AAzurity Pharmaceuticals

Approved

1 4

Haldol

Strattera

Intuniv

Bendopa

MMerz Pharmaceuticals GmbH

Abilify

Topamax

2 10

Mirapex

Boehringer Ingelheim

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tourette syndrome1 trial

Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome

Active, not recruiting·NNoema Pharma AG·Phase 2·NCT06315751·164 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gemlapodect. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gemlapodect compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gemlapodect. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Noema Pharma AG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNoema Pharma AG

Gemlapodect

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tourette syndrome1 trial

References

Drug Info

Quick Facts

Related News